| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 457,2 M € | +6.7% | 428,6 M € | -0.7% | 431,6 M € | +11.9% | 385,7 M € | +13.3% | 340,5 M € | +9.5% | 311,0 M € | +43.2% | 217,2 M € | +39.3% | 155,9 M € | +4.9% | 148,5 M € | -4.8% | 156,0 M € | +15.6% | 134,9 M € | +10.1% | 122,6 M € | -2.1% | 125,3 M € | +3.3% | 121,2 M € | -26.3% | 164,6 M € | -17.8% | 200,1 M € | +234.0% | 59,9 M € | — | ||
| EBITDA | 165,4 M € | +22.1% | 135,5 M € | -14.3% | 158,0 M € | +23.0% | 128,4 M € | +20.9% | 106,2 M € | -10.6% | 118,8 M € | +86.8% | 63,6 M € | +1.1% | 62,9 M € | +37.3% | 45,8 M € | -15.5% | 54,2 M € | +12.3% | 48,3 M € | -1.8% | 49,2 M € | +0.2% | 49,1 M € | +3.3% | 47,5 M € | -57.2% | 110,9 M € | +112.9% | 52,1 M € | -49.7% | 103,6 M € | +704.1% | -17,1 M € | |
| Operating profit | 105,2 M € | +39.9% | 75,2 M € | -8.5% | 82,2 M € | +43.7% | 57,2 M € | -1.5% | 58,0 M € | +12.6% | 51,6 M € | +61.0% | 32,0 M € | -7.9% | 34,8 M € | +222.8% | 10,8 M € | -63.1% | 29,2 M € | +16.1% | 25,1 M € | -5.0% | 26,5 M € | -0.9% | 26,7 M € | -1.9% | 27,2 M € | -69.8% | 90,2 M € | +175.9% | 32,7 M € | -64.3% | 91,5 M € | +542.2% | -20,7 M € | |
| Profit/loss | 80,1 M € | +36.3% | 58,8 M € | -5.8% | 62,4 M € | +44.8% | 43,1 M € | -0.9% | 43,5 M € | +10.9% | 39,2 M € | +84.4% | 21,3 M € | -17.8% | 25,9 M € | +276.5% | 6,9 M € | -76.5% | 29,2 M € | +249.2% | -19,6 M € | -195.3% | 20,5 M € | -8.2% | 22,4 M € | +9.4% | 20,4 M € | -6.7% | 21,9 M € | -13.8% | 25,4 M € | -71.0% | 87,8 M € | +387.5% | -30,5 M € | |
| Equity | 862,1 M € | +10.2% | 782,0 M € | +8.1% | 723,4 M € | +9.4% | 661,1 M € | +7.0% | 618,0 M € | +7.6% | 574,6 M € | +7.3% | 535,5 M € | +4.1% | 514,3 M € | +5.3% | 488,5 M € | +1.4% | 481,7 M € | +6.4% | 452,5 M € | -4.2% | 472,2 M € | +4.5% | 451,7 M € | +5.2% | 429,4 M € | +5.0% | 409,0 M € | +15.5% | 354,2 M € | +7.7% | 328,8 M € | +305.5% | 81,1 M € | |
| Total assets | 1,0 Md € | +6.7% | 939,5 M € | +0.6% | 933,7 M € | +9.6% | 852,2 M € | +15.8% | 736,2 M € | -1.0% | 743,8 M € | -1.2% | 752,6 M € | -3.0% | 776,3 M € | +8.0% | 718,8 M € | +9.2% | 658,5 M € | +24.8% | 527,7 M € | -2.1% | 539,1 M € | +1.2% | 532,9 M € | -1.3% | 539,7 M € | +15.0% | 469,3 M € | +3.8% | 452,0 M € | +21.3% | 372,7 M € | +15.8% | 321,9 M € | |
| Cash | — | — | — | — | — | — | 31,1 k € | — | 26,0 k € | -99.0% | 2,6 M € | +1.6% | 2,5 M € | +140.1% | 1,0 M € | +245.7% | 302,5 k € | +29.2% | 234,2 k € | -92.7% | 3,2 M € | +42.8% | 2,3 M € | +62.8% | 1,4 M € | +52.0% | 912,0 k € | |||||||||
| Debts | 135,5 M € | -10.5% | 151,4 M € | -4.6% | 158,7 M € | -7.0% | 170,6 M € | +52.4% | 112,0 M € | -31.2% | 162,8 M € | -24.1% | 214,5 M € | -17.2% | 259,2 M € | +13.9% | 227,5 M € | +28.9% | 176,5 M € | +135.9% | 74,8 M € | +12.6% | 66,5 M € | -17.7% | 80,8 M € | -26.4% | 109,8 M € | +83.9% | 59,7 M € | -38.4% | 97,0 M € | +125.6% | 43,0 M € | -82.1% | 239,9 M € | |
| Staff | 990,1 | 882,2 | 858,7 | 862,8 | 873,4 | 788,6 | 658,5 | 611,4 | 572,7 | 556,9 | 530,9 | 530 | 536,8 | 521,3 | 472,4 | 399,6 | 333,7 | 288,9 | ||||||||||||||||||
Private limited company · Geel · incorporated on 07/11/2001 · 990,1 ETP
Private limited company profitable and well capitalised. Cash position rising (+19.8%).
Solid counterparty for a standard engagement.
GENZYME FLANDERS is a Private limited company incorporated in 2001. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Geel. It employs on average 990,1 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette